Mercy BioAnalytics, a Natick, MA-based company focused on advancing extracellular vesicle-based liquid biopsies for the early detection of cancer, raised $41M in Series A funding.
The round was led by Novalis LifeSciences, with participation from Sozo Ventures, Hatteras Venture Partners, iSelect Fund, American Cancer Society BrightEdge, Broadway Angels, Labcorp and Bruker.
The company intends to use the funds to advance development and commercialization of its Halo test, for high-risk lung cancer screening, its lead clinical indication, and to advance clinical programs in additional indications, including ovarian cancer.
Led by CEO Dawn Mattoon, PhD., Mercy BioAnalytics is a biotechnology company leveraging a Halo liquid biopsy platform that utilizes biomarker co-localization to interrogate abundant, blood-based extracellular vesicles that carry cancer signatures from their parent cells. Its platform is designed to detect Stage I cancer, when it is most treatable, and enhance the quality of life for cancer patients and their families. Mercy’s initial focus is the early detection of ovarian and lung cancers.
FinSMEs
03/04/2023